A Trial Postmortem: Challenges in Conducting a Randomized, Double-blind, Phase 2 Study in Men with Castration-resistant Prostate Cancer

Double Blind ◽

Castration Resistant ◽

A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5111 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5111-TPS5111

Author(s):

Gautam Gopalji Jha ◽

Jeffrey S Miller

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Double Blind ◽

Castration Resistant ◽

Faculty Opinions recommendation of A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958957.793463459 ◽

2012 ◽

Author(s):

Tim Cundy

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Dose Finding ◽

Phase 2 ◽

Double Blind ◽

Castration Resistant ◽

Multicenter Phase ◽

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2012.09.008 ◽

2013 ◽

Vol 63 (2) ◽

pp. 189-197 ◽

Cited By ~ 124

Author(s):

Christopher C. Parker ◽

Sarah Pascoe ◽

Aleš Chodacki ◽

Joe M. O'Sullivan ◽

Josep R. Germá ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Dose Finding ◽

Phase 2 ◽

Double Blind ◽

Castration Resistant ◽

Multicenter Phase ◽

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Investigational New Drugs ◽

10.1007/s10637-012-9869-8 ◽

2012 ◽

Vol 31 (3) ◽

pp. 760-768 ◽

Cited By ~ 143

Author(s):

Kenneth J. Pienta ◽

Jean-Pascal Machiels ◽

Dirk Schrijvers ◽

Boris Alekseev ◽

Mikhail Shkolnik ◽

...

Keyword(s):

Prostate Cancer ◽

Monoclonal Antibody ◽

Human Monoclonal Antibody ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Chemokine Ligand ◽

Cc Chemokine Ligand 2 ◽

Chemokine Ligand 2

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30365-6 ◽

2018 ◽

Vol 19 (7) ◽

pp. 975-986 ◽

Cited By ~ 99

Author(s):

Noel Clarke ◽

Pawel Wiechno ◽

Boris Alekseev ◽

Nuria Sala ◽

Robert Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Castration Resistant

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of Oncology ◽

10.1093/annonc/mdr336 ◽

2012 ◽

Vol 23 (1) ◽

pp. 53-58 ◽

Cited By ~ 24

Author(s):

K.N. Chi ◽

E. Beardsley ◽

B.J. Eigl ◽

P. Venner ◽

S.J. Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Oncology Group ◽

Urologic Oncology ◽

Oncology Group Study ◽

Castration Resistant ◽

Phase 2 Study ◽

Previously Treated

Abstract LB-224: A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2012-lb-224 ◽

2012 ◽

Author(s):

Emmanuel S. Antonarakis ◽

Elisabeth I. Heath ◽

David C. Smith ◽

Dana Rathkopf ◽

Amanda L. Blackford ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Randomized Phase 2

Abituzumab (Di17E6, Emd 525797) Treatment for Chemotherapy-Naive Patients with Asymptomatic or Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Primary Outcomes of the Placebo-Controlled Phase 2 Study Perseus (Nct01360840)

Annals of Oncology ◽

10.1093/annonc/mdu336.20 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

K. Miller ◽

M. Hussain ◽

S. Le Moulec ◽

I. Rybicka ◽

R. Bruns ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5030 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5030-5030 ◽

Cited By ~ 2

Author(s):

Maha Hussain ◽

Kurt Miller ◽

Ilona Rybicka ◽

Rolf Bruns

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16080 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16080-e16080

Author(s):

Edwin M. Posadas ◽

Mourad Tighgohart ◽

YI-TSUNG LU ◽

Dolores Di Vizio ◽

David M. J. Hoffman ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Visceral Metastases